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Volume 52, Number 3 Abstracts 803and CLI on presentation (P  .002). Age 50 was also an independent
predictor of limb loss compared with age 60 (P  .05).
Conclusion: Endovascular options are commonly being used in young
patients, especially claudicants, but patency rates and outcomes remain very
poor.
Demographic and clinical characteristics by age group
Characteristics 50 years 51-60 years 60 years P
Patient level (n  97) (n  103) (n  98)
Mean SD Mean SD Mean SD
Age at surgery, mean
 SD, y
45  5 56  3 73  8 .001
% (No.) % (No.) % (No.)
Male 57 (55) 65 (67) 63 (62) .44
History
CAD 43 (42) 55 (57) 62 (60) .03
ESRD 6 (6) 19 (20) 13 (13) .02
Hypertension 76 (74) 82 (84) 87 (85) .17
Hypercholesterolemia 58 (56) 64 (66) 69 (60) .28
Diabetes 38 (37) 43 (44) 62 (61) .002
Smoking 83 (80) 79 (81) 62 (61) .003
Hypercoagulable state 16 (15) 5 (5) 3 (2) .004
Limb level (n  139) (n  151) (n  119)
Procedure
Percutaneous 40 (55) 52 (78) 52 (61) .15
Open surgery 57 (79) 46 (69) 47 (57) .15
Hybrid 3 (5) 2 (4) 1 (1) .15
Indication
Claudication 46 (64) 45 (68) 37 (42) .16
Critical limb ischemia 54 (75) 54 (83) 63 (77) .16Comparison of Ultrasound Accelerated Thrombolysis Versus Simple In-
fusion Catheter Directed Thrombolysis for Acute Arterial Thrombosis
Parth S. Shah,MBBSMPH, Anil Hingorani,MD, Enrico Ascher,MD,Uma
Ballehaninna, MBBS, Alexander Shiferson, DO, Natalie Marks, RVT, Kapil
Gopal, MD, Daniel Jung, DO and Theresa Jacobs, PhD, Maimonides
Medical Center, Brooklyn, NY
Objectives: Catheter-directed intra-arterial thrombolysis for acute
peripheral arterial ischemia has become a standard practice for acute
arterial thrombosis. There has been significant amount of literature
published as far as the choice of the thrombolytic agent and injection
techniques. One technique used to accelerate thrombolysis is with the
use of ultrasound imaging (EKOS). We looked at our experience to
compare the outcomes with a simple side-hole infusion catheter (Uni-
fuse) vs EKOS catheters.
Methods: We retrospectively reviewed our data set from January
2006 to August 2008 for all the patients undergoing catheter-directed
thrombolysis for acute lower extremity arterial ischemia. The primary
comparison variables were the duration of thrombolysis and technical
success rate. The technical success rate was defined as complete or nearly
complete clearance of clot burden allowing intervention in form of
percutaneous transluminal angioplasty (PTA) and/or stenting. The data
were also stratified according to the location of the thrombus, complica-
tions, mortality, and limb loss rates. Tissue plasminogen activator (TPA)
was infused at 0.5 to 2.0 mg/h and patients underwent serial angiogra-
phy every 12 to 24 hours.
Results:There were 69 cases of peripheral catheter-directed thrombol-
ysis with the Unifuse catheter and 22 were performed using the EKOS
catheter during the study period. The average duration of thrombolysis was
1.65 days (SD, 0.83) in the Unifuse catheter group vs 1.9 days (SD, 0.92) in
the EKOS catheter group (P  .22). Technical success was achieved in 72%
in the Unifuse group vs in 86% in the EKOS group (P  .31). Ten of 69
(14%) in Unifuse group and 2 of 22 (9%) in the EKOS group had limb loss
(P  .46). Complications were compartment syndrome requiring fas-
ciotomy and bleeding requiring premature cessation of thrombolysis. No
deaths occurred as an immediate result of complications. The complication
rate was 13% in the Unifuse group vs 10% in the EKOS group (P  .46).
Conclusions: There was no statistically significant difference in the
outcomes in catheter-directed thrombolysis in the treatment of acute
arterial ischemia using the Unifuse catheter vs the more expensive EKOS
catheter.
Cryoplasty Offers No Advantage Over Standard Balloon Angioplasty
for the Treatment of In-Stent Restenosis
Susanna H. Shin, Donald Baril, Rabih Chaer, MD, Michel Makaroun, MD,
Robert Rhee, MD, and Luke Marone, MD, UPMC, Pittsburgh, Pa
Objectives: In-stent restenosis is the primary failure mode of endo-
vascular treatment of occlusive disease in the femoropopliteal segment.
Cryoplasty has been proposed to reduce intimal hyperplasia through
induction of apoptosis. We sought to evaluate the efficacy of cryoplasty
for treatment of in-stent restenosis compared with conventional balloon
angioplasty (CBA).
Methods: After IRB approval, a retrospective record review was per-
formed of reinterventions for in-stent restenosis by a single vascular surgery
group at a university hospital. Reinterventions involving cryoplasty and CBA
were evaluated at 1, 3, 6, and 12 months after intervention with duplex
imaging to identify significant recurrent stenosis utilizing established veloc-
ity criteria. Data collected included basic demographic information and
comorbidities as well as time to restenosis. Statistical analysis was performed
using Kaplan-Meier survival curves with the log rank test, Wilcoxon rank
test, and Cox proportional hazards models.
Results: FromDecember 2004 toNovember 2009, 76 reinterventions
were performed using CBA (n  39) or cryoplasty (n  37) for in-stent
restenosis without placement of additional stents. Periprocedural technical
success (30% residual stenosis) was 100% for both groups, with no com-
plications. The two cohorts were statistically similar in mean age, gender
distribution, comorbidities (including active tobacco use), and use of statins,
aspirin, and Plavix. However, the mean lesion length was significantly
longer in the cryoplasty cohort (CBA: 140.9 mm, Cryo: 191.7 mm; P 
.032). The mean time to recurrent stenosis or need for additional
secondary intervention was significantly shorter for the cryoplasty cohort
than for the CBA, 4.09 and 10.79 months, respectively (P  .0001).
Recurrent stenosis-free survival was significantly lower in the cryoplasty
cohort at 3 months (CBA: 96.9%, Cryo: 88.9%) and 6 months (CBA:
84.0%, Cryo: 43.8%; P  .0089).Conclusions: Cryoplasty as a modality for treatment of in-stent steno-
sis in the femoropopliteal segment offers no benefit over CBA.
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cularization
Mounir J. Haurani, MD, Mark F. Conrad, MD, Vikram Paruchuri, and
Richard P. Cambria, MD, Massachusetts General Hospital, Boston, Mass
Objective: Percutaneous revascularization (PTA) of infrainguinal oc-
clusive disease is associated with a significant recurrence rate, with a 15% to
25% reintervention rate to maintain secondary patency. Other studies have
focused on clinical predictors of such failure, but little is known of the
anatomy of such failures, which is the goal of this study.
Methods: Of 1100 limbs that underwent infrainguinal PTA from
2002-2007, 40% failed based on worsening ABIs, clinical symptoms, ampu-
tation, or reintervention. A total of 150 limbs underwent femoral-popliteal
PTA and had follow-up arteriograms for evaluation. Lesions were stratified
into proximal, middle (adductor canal), and distal (popliteal). Angiographic
findings from the initial PTA were compared with the follow-up study.
Results: Of the 150 limbs in the cohorts, 38% underwent initial PTA
for critical limb ischemia, with 10% limb loss. The mean length of time to
recurrence was 13.2 months, with 70% of patients recurring by that time
point. The distribution of disease was not different between the initial PTA
and the follow-up angiography (70% vs 64% [P .2] proximal, 79% vs 78%
[P  .1] middle, and 28% vs 30% [P  .8] distal femoral-popliteal). There
was no change in multilevel disease from initial PTA either (64% vs 58% P
.3). Significantly more middle femoral-popliteal segments were initially
occluded (25% proximal, 33%middle, and 12% distal; P .001). An initially
occluded segment did not increase the likelihood of new or worsening
disease on repeat angiography. Tibial runoff deteriorated in 11% of patients
but did not correlate with amputation, initial lesion location, or severity.
Initially, 40% of the limbs treated underwent stenting in at least one
segment; this did not predict worsening disease. In 68% of the limbs treated,
the site of recurrence was the same as the initial PTA site, and in 16%, the
disease was immediately adjacent to the initial PTA site.
Conclusions: Recurrent lesions after infrainguinal PTA tend to occur
within the first year and most occur at or immediately adjacent to the site of
initial treatment. There was no difference in the location of the recurrent
disease when compared with primary PTA site. Presence of an occlusion was
not predictive of worsening disease within the femoral-popliteal artery or the
location of the recurrence.
Scientific Session II
Role of IVUS Versus Venograms in Assessment of Iliac-Femoral Vein
Stenosis
Anil Hingorani,MD, Saadi Alhabouni, MD, Enrico Ascher, MD, Natalie
Marks, MD RVT, Alexsander Shiferson, DO, Kapil Gopal, MD, Daniel
Jung, DO, and Theresa Jacob, PhD,MaimononidesMedical Center, Brook-
lyn, NY
Objective: Lower extremity venous stasis disease could be related to
outflow obstruction in the iliac-femoral vein segments due to stenosis or
extrinsic compression. Conventional methods to assess these vein segments
include transcutaneous ultrasonography and ascending venography. The
transcutaneous approach has a low sensitivity, and venography can miss
significant lesions as the assessment is undertaken in a single view. We
assessed the role of intravenous ultrasound (IVUS) imaging in detecting the
location as well as the degree of stenosis in the iliac-femoral vein segments.
Methods: IVUS and ascending venography were used to evaluate
outflow obstruction/stenosis in 104 patients with chronic lower extremity
venous stasis disease. The location and degree of any stenosis were noted. A
significant stenosis was defined as a 50% reduction in the diameter of the vein
relative to the adjacent vein segments. Patients with significant stenosisunderwent venous stenting to restore outflow. The results of venography
and IVUS were compared.
Results: Forty-six (44.2%) patients had no evidence of stenosis on
venography or IVUS and hence received no stents, but 58 (55.8%) had
significant stenotic lesions on IVUS. Among those, 10 (17.2%) had no
detectable lesion on venogram and would have been missed. In 24 patients
(41.4%), venography failed to identify all stenotic lesions or resulted in
inaccurate localization of the lesion. Only 24 patients (41.4%) had stenotic
lesions on venogram that conformed anatomically to the lesions detected on
IVUS.
Conclusions: In assessing patients with lower extremity venous stasis
disease for iliac-femoral vein stenosis/obstruction, venography alone can
result in poor localization (50% specificity) and can even miss significant
stenotic lesions (82.8% sensitivity). IVUS is a more sensitive and accurate
method and should be included in all such evaluations.
Venous Ablation Can Be Performed Safely on High-Risk Patients
Kathleen J. Ozsvath, MD, Stephanie Saltzberg, MD, John B. Taggert, MD,
Benjamin B. Chang, MD, Paul B. Kreienberg, MD, Manish Mehta, MD,
MPH, Philip S. K. Paty, MD, Sean P. Roddy, MD, Yaron Sternbach, MD,
and R. Clement Darling III, MD, Albany Medical College, Albany, NY
Introduction: Patients with a previous history of deep vein thrombosis
(DVT) or a family history of DVT are considered at high risk for thrombotic
complications (DVT) after endovenous ablation (EVA). In this study, we
examine our outcomes on patients presenting for “high-risk” EVA.
Methods:We reviewed our vascular registry for all patients undergoing
EVA from 2006-2008. All patients were evaluated with venous ultrasonog-
raphy and initially treated with a minimum of 3 months of compression
stockings. EVA candidates were treated with laser ablation or radiofrequency
ablation using a standardized technique. All patients who were identified as
potential high risk for DVT had hematology consultation and were pre-
scribed periprocedural anticoagulation prophylactically. Postprocedural ul-
trasonography was performed at 1 week, 1 month, 3 months, and every 6
months thereafter for 2 years.
Results: A total of 685 EVA were performed (480 laser, 205 radiofre-
quency), most in the great saphenous veins. A subgroup of 15 patients
(2.1%) was identified to be high risk for DVT.Mean age was 44 years. CEAP
classifications ranged from 2 to 6, with ankle edema being themost common
diagnosis. The immediate technical success rate was 99.6%. Access failure
occurred in three patients (0.4%). The most common postprocedural com-
plications included bruising in 203 (29%), phlebitis in branch varicosities in
28 (4%), and heat induced thrombus formation in 13 (1.9%). There was no
significant difference between laser and radiofrequency groups. None of the
presumed hypercongealable patients developed thrombotic complications.
There were no deaths in this series. Mean follow-up was 6 months (range,
1-27 months). Ancillary procedures were performed in 19%, including stab
phlebectomy, sclerotherapy, and perforator injection or ablations. All pa-
tients remain successfully ablated to date.
Conclusions: In our experience, EVA can be safely performed in
appropriate candidates with excellent clinical outcomes and minimal mor-
bidity and mortality. Preliminary data suggests that patients with hyperco-
agulable conditions or strong family history of thrombosis can be considered
for EVA with periprocedural anticoagulation.
Clinical Outcomes With Covered Stent Placement for Central Venous
Occlusive Disease in Hemodialysis Patients
Javier E. Anaya-Ayala, MD, Cherie Obilom, BS, Zulfiqar F. Cheema, MD,
PhD, Joseph J. Naoum, MD, Jean Bismuth, MD, Mark G. Davies, MD,
PhD, Alan B. Lumsden, MD, and Eric K. Peden, MD, Methodist DeBakey
Heart and Vascular Center, Houston, Tex
Objectives:The use of covered stents (CSs) has been proposed as a new
treatment option for central venous occlusive disease (CVOD) in hemodi-
alysis patients. Among its advantages include the mechanical support of
bare-metal stents while providing an inert and stable intravascular matrix for
endothelialization. The aim of this study is to evaluate the efficacy and
durability of CSs in treating central venous stenosis while preserving hemo-
dialysis access patency.
Methods: A retrospective review was performed in all patients with
symptomatic CVOD manifested with venous hypertension or access mal-
function and treated by means of CS from April 2007 to March 2010. The
Gore Viabahn Endoprosthesis stent graft was implanted in all cases. Patients’
demographics, stenotic lesions location, stent graft, and patency were deter-
mined; complications, reintervention, and factors influencing their out-
comes were examined.
Results: Twenty patients (60% men) with a mean age of 56 years
(range, 28 to 86) primarily underwent CS placement for CVOD. Of the 20,
18 (90%) had history of arterial hypertension, 13 (65%) were diabetic, and 4
(20%) had peripheral arterial disease. All patients had a history of multiple
central catheter placements. The indications for the CS placement were
access malfunction with angioplasty-resistant lesions in 12 patients (60%)
